| Original language | English (US) |
|---|---|
| Pages (from-to) | E7-E10 |
| Journal | American Journal of Hematology |
| Volume | 97 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2022 |
Funding
This study was supported by Cancer Center Support Grant/Core Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748); Raajit K. Rampal is supported by National Cancer Institute P01 CA108671 11. Amber C. King has received advisory/consulting fees from: Astellas, Abbvie, and Blueprint Medicines. Raajit K. Rampal has received consulting fees from: Constellation, Novartis, Kartos, Incyte, Celgene/BMS, Promedior, CTI, Blueprint, Stemline, Galecto, Pharmaessentia, Abbvie and research funding from Incyte, Constellation, Stemline, and Zentalis. Aaron D. Goldberg has served as a consultant or on advisory boards for AbbVie, Aptose, Astellas, Celgene, Daiichi Sankyo, and Genentech, has received research funding from AbbVie, Aptose, Cellularity, ADC Therapeutics, Aprea, AROG, Pfizer, and Prelude, and has received honoraria from Dava Oncology. Maximilian Stahl has consulted for the Boston Consulting Group. Michael J. Mauro has disclosed the following relationships: Novartis; consulting/advisory/research support (institution), Takeda; consulting/advisory/research support (institution), Sun Pharma/SPARC; research support (institution), Bristol Myers Squibb; consulting/advisory, Pfizer: consulting/advisory. Martin S. Tallman has disclosed the following relationships: Abbvie: Research Funding; Cellerant: Research Funding; Orsenix: Research Funding; ADC Therapeutics: Research Funding; BioSight: Membership on an entity's Board of Directors or advisory committees and Research Funding; Glycomimetics: Research Funding; Rafael: Research Funding; Amgen: Research Funding; Bioline rx: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; KAHR: Membership on an entity's Board of Directors or advisory committees; Rigel: Membership on an entity's Board of Directors or advisory committees; Delta Fly Pharma: Membership on an entity's Board of Directors or advisory committees; Oncolyze: Membership on an entity's Board of Directors or advisory Committees; Jazz Pharma: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; UpToDate: Patents & Royalties. Eunice S. Wang has received consulting fees from Abbvie, Amgen, Astellas, BMS, Genentech, Gilead, GlaxoSmithKline, Jazz, Kite, Kura, Mana Therapeutics, Novartis, Stemline, Takeda; speaker roles for Astellas, Dava Oncology, Kura, Pfizer, Stemline; Data monitoring committees for Abbvie and Rafael Pharmaceuticals. Andrew T. Kuykendall has received consulting feels/honoraria from Blueprint, Novartis, Incyte, Celgene/BMS, Abbvie, CTI Biopharma, Pharmaessentia, Protagonist and research funding from Protagonist, Prelude, and Sierra. The remaining authors have no relevant disclosures. National Cancer Institute, Grant/Award Number: P01 CA108671 11; Cancer Center Support Grant/Core Grant to Memorial Sloan Kettering Cancer Center, Grant/Award Number: P30 CA008748 Funding information
ASJC Scopus subject areas
- Hematology